Skip to content

Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00524732
Enrollment
7156
Registered
2007-09-05
Start date
2004-09-30
Completion date
2005-09-30
Last updated
2014-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diphtheria, Pertussis

Keywords

Pertussis, Tetanus, Diphtheria

Brief summary

To compare the reactogenicity of ADACEL® vaccine given at intervals of 2 to 9 years with the reactogenicity of ADACEL® vaccine given at an interval of 10 or more years following the last previous administration of vaccine containing Diphtheria and Tetanus Toxoids (referred to as TD/Td).

Interventions

BIOLOGICALTetanus and diphtheria toxoids and acellular pertussis

0.5 mL, Intramuscular

Sponsors

Sanofi Pasteur, a Sanofi Company
Lead SponsorINDUSTRY

Study design

Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
7 Years to 19 Years
Healthy volunteers
Yes

Inclusion criteria

* Age \> 7 years and \< 20 years. * Signed and dated IRB-approved informed consent form obtained from the participant, parent or legal guardian prior to the first study intervention. * Judged to be in good health on the basis of reported medical history. * Available for planned length of the study. * Participant or parent or legal guardian (as applicable) can read and write English and can understand the informed consent documents and the study instructions. A participant eleven years of age or older who meets an exclusion criterion may not be enrolled in the study but nonetheless may participate in the vaccination program, at the discretion of the Prince Edward Island public health authorities). A participant younger than eleven years of age who meets an exclusion criterion may not be enrolled in the study and may not participate in the vaccination program.

Exclusion criteria

* Known or suspected allergy to ADACEL®, any of the vaccine's components, or prior allergic reaction to Diphtheria or Tetanus Toxoids or Acellular Pertussis Vaccine. * Planned receipt of any other vaccine within the 14 days following administration of ADACEL® vaccine in this study. * Any other medical condition that in the opinion of the investigator would cause an unexpected hazard or interfere with the study objective. * Receipt of TD/Td within the preceding 12 months. * Known or suspected to be pregnant. A participant eleven years of age or older who meets an exclusion criterion may not be enrolled in the study but nonetheless may participate in the vaccination program, at the discretion of the Prince Edward Island public health authorities). A participant younger than eleven years of age who meets an exclusion criterion may not be enrolled in the study and may not participate in the vaccination program.

Design outcomes

Primary

MeasureTime frame
To provide safety information on ADACEL® vaccine given at different time intervals.Up to 114 months post-vaccination

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026